Recent coverage of retatrutide (Eli Lilly’s investigational “triple agonist” weight-loss drug targeting GIP, GLP-1, and glucagon receptors) is focused on late-stage trial results showing very large average weight loss—but also a signal of meaningful tolerability/side-effect tradeoffs for some participants.[1][4]
Latest headline results (late-stage)
- In one widely reported late-stage study, Eli Lilly said retatrutide produced about 28.7% average weight loss among the highest-dose group who stayed on treatment, over 68 weeks; when accounting for all treated participants (including those who stopped early), the efficacy was reported as about 23.7%.[1]
- Another report tied to the same broader news cycle described results as comparable to bariatric surgery and highlighted that a substantial share of participants on the 12 mg dose lost up to ~30% body weight (over the trial timeframe described in the report).[4]
What major news outlets emphasized
- Magnitude of weight loss: Multiple outlets characterized the results as “stunning”/“dramatic,” with comparisons to prior obesity medications (e.g., semaglutide and tirzepatide) often mentioned in context.[4]
- Discontinuation / side effects: Reporting also noted that side-effect rates were high and that many participants discontinued, including people who felt they were losing too much weight.[1]
Context: why retatrutide is “different”
- Retatrutide is commonly described as a triple agonist (GIP + GLP-1 + glucagon), with the glucagon effect often cited as one reason it may drive additional weight/fuel-energy changes beyond typical single/double incretin strategies.[4]
If you tell me whether you want (a) the most important numbers only, (b) a quick pros/cons summary, or (c) the latest by trial (and whether to focus on obesity alone vs obesity + comorbidities like knee osteoarthritis), I can tailor the rundown.
Sources
A new weight loss injection called retatrutide has shown remarkable results in…
www.diabetes.co.ukParticipants of a phase III trial of investigational weight-loss drug retatrutide showed an average weight loss of almost 30% and “substantial” relief from knee osteoarthritis, manufacturer Eli Lilly and Company has announced. In a statement published on 11 December 2025, Eli Lilly reported results from its TRIUMPH-4 trial, which involved 445 participants aged over 18 […]
pharmaceutical-journal.comFindings demonstrated that participants with obesity lost more than 24% of their starting body weight within 48 weeks of treatment with the highest dose of retatrutide. Additionally, 100% of the participants taking either of the two higher doses (8 mg and 12 mg) lost at least 5% or more of their body weight. The results indicate that retatrutide has an overall safety and tolerability profile similar to other nutrient-stimulated hormone-based therapies, such as GLP-1 receptor agonists approved...
diabetes.orgTransformation videos highlighting crazy weight loss journeys are taking over social media.
www.cbsnews.com"Retatrutide delivered powerful weight loss," Leerink Partners analyst David Risinger told investors on Thursday morning. The study's results are the latest signal that retatrutide may be the most effective weight-loss medication in development. As such, retatrutide is a highly anticipated addition to Lilly's (LLY) obesity portfolio, which already includes Zepbound, a weekly GLP-1/GIP shot, and Foundayo, a daily non-peptide GLP-1 pill. It is sometimes referred to as "triple G" because it...
www.morningstar.comPeople treated with injections of retatrutide—an agonist of glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors—lost substantially more weight than those who received a placebo, according to results from a phase 2 trial involving 338 adults with obesity or...
jamanetwork.comEli Lilly's next-gen obesity drug delivered major weight loss in a trial, but some patients stopped using it after losing too much weight.
www.statnews.comThe results of the drug are comparable to what is seen with bariatric surgery, according to Eli Lilly.
abcnews.com(UPDATED) The once-weekly injectable targeting three hormone receptors hints at “fundamental change” for cardiometabolic disease.
www.tctmd.com